| Purpose: Objective To observe the clinical effect of xinkaikujiang and Jianpi Huayu Decoction in the treatment of chronic atrophic gastritis with cold and heat syndrome,spleen deficiency and blood stasis syndrome,and to evaluate the effectiveness of the treatment.Material and Method: From September 2018 to December 2019,36 patients with chronic atrophic gastritis of mixed cold and heat,spleen deficiency and blood stasis type were included.The experimental group(traditional Chinese medicine group)and the control group(placebo group)were randomly divided into 24 cases and 12 cases.All patients were followed up for 48 weeks.The total and individual TCM symptom scores,syndrome efficacy and quality of life of the two groups were compared before,after and after medication;The curative effect,pathological score,Olga and olgim stages before and after treatment were compared.Results:1.TCM symptom score:(1)total score: after medication and follow-up,the improvement of the experimental group was better than that of the control group,and there were significant differences between the two groups(P < 0.01);Before and after medication and follow-up,there were significant differences in the experimental group(P < 0.01),but there were no significant differences in the control group(P > 0.05).There was no significant difference between the two groups(P > 0.05).(2)Single score: in the six single symptoms of gastric distension,stomachache,anorexia,fatigue,heartburn,dry mouth and bitter mouth,the improvement of the experimental group was better than that of the control group after taking the medicine and following up,and there were statistical differences between the two groups(P < 0.05);Before and after medication and follow-up,there were significant differences in the six single points in the experimental group(P < 0.05),while there were no significant differences in the six single points in the control group(P > 0.05).Compared with the follow-up,there was no significant difference between the experimental group and the control group(P > 0.05).2.TCM syndrome curative effect:(1)after taking medicine,the total effective rates of the experimental group and the control group were 91.67% and 25% respectively,and the improvement of the experimental group was significantly better than that of the control group,with significant statistical difference(P < 0.01)(2)After follow-up,the total effective rates of the experimental group and the control group were 91.67% and 33.33%,respectively.The improvement of the experimental group was significantly better than that of the control group,with significant statistical difference(P < 0.01).3.Gastroscopic effect: after taking medicine,the improvement of the experimental group was better than that of the control group,and the comparison between the two groups showed statistical difference(P < 0.05);Before and after treatment,the intra group comparison of the degree of gastroscopic mucosal remission in the experimental group had significant statistical difference(P < 0.01),and the intra group comparison of the improvement in the control group had no statistical difference(P > 0.05).4.Pathological score: there was no significant difference in atrophy and intestinal metaplasia between the two groups(P > 0.05);Before and after taking the medicine,there were significant differences in the atrophy and intestinal metaplasia of the experimental group(P <0.05),but there were no significant differences in the atrophy and intestinal metaplasia of the control group(P > 0.05).5.Cancer risk assessment: in Olga staging,the proportion of 0,I,II,III and IV staging in the experimental group was 0,33.33%,12.5%,29.17% and 25% respectively before medication,and 25%,33.33%,16.67%,12.5% and 12.5% respectively after medication;In the control group,the proportion of staging was 0,33.33%,16.67%,25%,25% before taking medicine,and 8.33%,33.33%,8.33%,25%,25% after taking medicine.In terms of olgim staging,the proportions of 0,I,II,III and IV staging before treatment were 8.33%,16.67%,29.17%,25%and 20.83% respectively in the experimental group,and those after treatment were 20.83%,33.33%,20.83%,12.5% and 12.5% respectively;33%,33.33%,16.67%,25% and 16.67% respectively in the control group before taking medicine,and 16.67%,25%,16.67%,25% and16.67% respectively after taking medicine.6.Quality of life evaluation: in the aspect of Pro scale score of chronic gastritis,the improvement of the experimental group was better than that of the control group after taking medicine and following up,and there were significant differences between the two groups(P< 0.01);Before and after medication and follow-up,there were significant differences in the experimental group(P < 0.01),and there were no significant differences in the pro score of chronic gastritis in the control group(P > 0.05).Compared with the follow-up,there was no significant difference in Pro score of chronic gastritis between the experimental group and the control group(P > 0.05).Conclusion:1.Xinkaikujiang and jianpihuayu decoction have certain clinical efficacy in the treatment of CAG patients with cold and heat syndrome,spleen deficiency and blood stasis syndrome,mainly reflected in the improvement of clinical symptoms and quality of life.2.Xinkaikujiang and jianpihuayu can improve the endoscopic performance of patients,reduce the risk stratification of Olga and olgim,and reduce the risk of gastric cancer to a certain extent. |
PDF Full Text Request